The Role of Public Health in Mental Health Promotion
Mental illness contributes a substantial burden of disease worldwide. Globally, approximately 450 million persons suffer from mental disorders (1) , and one fourth of the world's population will develop a mental or behavioral disorder at some point during their lives (2) . Mental disorders account for approximately 25% of disability in the United States, Canada, and Western Europe and are a leading cause of premature death (1, 3) . In the United States, approximately 22% of the U.S. adult population has one or more diagnosable mental disorders in a given year (3) . The estimated lifetime prevalences for mental disorders among the U.S. adult population are approximately 29% for anxiety disorders, 25% for impulse-control disorders, 21% for mood disorders, 15% for substance-use disorders, and 46% for any of these disorders (4) . In addition, an estimated one in 10 children in the United States has a mental disorder that causes some level of impairment (5) . The effects of mental illness are evident across the life span, among all ethnic, racial, and cultural groups, and among persons of every socioeconomic level (6) . Moreover, mental illness costs the United States an estimated $150 billion annually, excluding the costs of research (7) .
Mental health is integral to overall health and well-being and should be treated with the same urgency as physical health (3, 7) . Mental illness can influence the onset, progression, and outcome of other illnesses and often correlates with health risk behaviors such as substance abuse, tobacco use, and physical inactivity (8) . Depression has emerged as a risk factor for such chronic illnesses as hypertension, cardiovascular disease, and diabetes and can adversely affect the course and management of these conditions (8) .
Treatment for mental disorders is available and effective (3, 5) . However, the majority of persons with diagnosed mental disorders do not receive treatment (4) . The challenges for public health are to identify risk factors, increase awareness about mental disorders and the effectiveness of treatment, remove the stigma associated with receiving treatment, eliminate health disparities, and improve access to mental health services for all persons, particularly among populations that are disproportionately affected (1, 3) . Public health agencies can incorporate mental health promotion into chronic disease prevention efforts, conduct surveillance and research to improve the evidence base about mental health in the United States, and collaborate with partners to develop comprehensive mental health plans to enhance coordination of care.
CDC has mobilized multiple efforts to assess and address mental health and well-being. Data on mental health, risk behaviors, and comorbidity of mental illness and chronic disease are collected through various national surveillance initiatives. CDC also collaborates with the World Federation for Mental Health to address stigma, a pervasive barrier to seeking treatment, through promotion of public awareness campaigns, such as World Mental Health Day. As the nation's premier public health agency, CDC is well-positioned to expand its role in safeguarding mental health by supporting the efforts of other health agencies, such as the Substance Abuse and Mental Health Services Administration and the National Institute of Mental Health, through continued surveillance of mental illness and risk behaviors in the U.S. population and promotion of mental health across the life span. estimate rates of parent-reported ADHD diagnosis and medication treatment for ADHD, CDC analyzed data from the 2003 National Survey of Children's Health (NSCH). This report describes the results of that analysis, which indicated that, in 2003, approximately 4.4 million children aged 4-17 years were reported to have a history of ADHD diagnosis; of these, 2.5 million (56%) were reported to be taking medication for the disorder. Because both substantial health risks and benefits might be associated with medication treatment for ADHD, further study of this population of children with ADHD is needed.
NSCH is a survey about the physical and emotional health of civilian, noninstitutionalized, U.S. children aged <17 years (6) (1) six or more of the following symptoms of inattention have persisted for at least 6 months to a degree that is maladaptive and inconsistent with developmental level:
Inattention (a) often fails to give close attention to details or makes careless mistakes in school work, work, or other activities (b) often has difficulty sustaining attention in tasks or play activities (c) often does not seem to listen when spoken to directly (d) often does not follow through on instructions and fails to finish school work, chores, or duties in the workplace (not because of oppositional behavior or failure to understand instructions) (e) often has difficulty organizing tasks and activities (f ) often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (such as school work or homework) (g) often loses things necessary for tasks or activities (e.g., toys, school assignments, pencils, books, or tools) (h) is often easily distracted by extraneous stimuli (i) is often forgetful in daily activities (2) six or more of the following symptoms of hyperactivity-impulsivity have persisted for at least 6 months to a degree that is maladaptive and inconsistent with developmental level:
Hyperactivity (a) often fidgets with hands or feet or squirms in seat (b) often leaves seat in classroom or in other situations in which remaining seated is expected (c) often runs about or climbs excessively in situations in which it is inappropriate (in adolescents or adults, might be limited to subjective feelings of restlessness) (d) often has difficulty playing or engaging in leisure activities quietly (e) is often "on the go" or often acts as if "driven by a motor" (f ) often talks excessively Impulsivity (g) often blurts out answers before questions have been completed (h) often has difficulty awaiting turn (i) often interrupts or intrudes on others (e.g., butts into conversations or games) B. Some hyperactive-impulsive or inattentive symptoms that caused impairment were present before age 7 years. C. Some impairment from the symptoms is present in two or more settings (e.g., at school [or work] and at home). D. Clear evidence of clinically significant impairment in social, academic, or occupational functioning. E. Symptoms do not occur exclusively during the course of a pervasive developmental disorder, schizophrenia, or other psychotic disorder and are not better accounted for by another mental disorder (e.g., mood disorder, anxiety disorder, dissociative disorder, or personality disorder).
the National Immunization Survey sampling frame. One child was randomly selected from households with at least one child aged <17 years. Parents or guardians responded to survey items on behalf of 102,353 sample children (completion rate: 68.8%). NSCH data were weighted to estimate national and state-specific rates of ADHD diagnosis and medication treatment among children aged 4-17 years. As a proxy for ADHD diagnosis, respondents were asked, "Has a doctor or health professional ever told you that [child] has attention-deficit disorder or attention-deficit/hyperactivity disorder, that is, ADD or ADHD?" If an ADHD diagnosis was indicated, respondents were asked, "Is [child] currently taking medication for ADD or ADHD?" Estimates of reported ADHD diagnosis, current medication treatment among those with ADHD, and current medication treatment for ADHD among all children aged 4-17 years were calculated. Rates of medication treatment for ADHD among all children aged 4-17 years were calculated by using the number of children currently receiving medication as the numerator and all families who responded to the ADHD diagnosis question (affirmatively or negatively) as the denominator. Statistical software was used to adjust for the complex sampling design of NSCH. Statistical significance was concluded for those comparisons yielding an alpha level <0.05. Seventy-four sample children were excluded from sociodemographic comparisons because of missing data on their sex.
Prevalence and national population estimates of parentreported ADHD diagnosis were calculated and compared by selected sociodemographic characteristics (Table) . In 2003, approximately 7.8% (4,418,000; 95% confidence interval [CI] = 4,234,000-4,602,000) of U.S. children aged 4-17 years had ever had ADHD diagnosed. ADHD diagnosis was reported approximately 2.5 times more frequently among males than females ( Figure 1 ). Prevalence of reported ADHD increased with age and was significantly lower among children aged 4-8 years compared with children aged >9 years (Table) . The greatest prevalence was noted among males aged 16 years (14.9%) and females aged 11 years (6.1%). The prevalence of reported ADHD diagnosis was significantly higher among non-Hispanic, primarily English-speaking, and insured children. Moreover, prevalence rates were significantly higher for children in families in which the most highly educated adult was a high school graduate (or had completed 12 years of education), compared with children in families in which the most highly educated adult had a higher or lower level of education. ADHD diagnosis among males was reported significantly more often in families with incomes below the poverty threshold (<100%) than in families with incomes at or above the poverty threshold. Rates of reported diagnosis among females were not significantly different across the three levels of poverty. Prevalence varied substantially by state, from a low of 5.0% in Colorado to a high of 11.1% in Alabama (Figure 2 ). In 2003, an estimated 4.3% (2,473,000; 95% CI = 2,338,000-2,607,000) of children aged 4-17 years were reported to have ever had an ADHD diagnosis and were taking medication for the disorder. Rates of medication treatment for ADHD varied by age and sex and ranged from 0.3% to 9.3% (Figure 1) . Regardless of sex, the overall medicationby-age patterns were curvilinear, with prevalence of medication treatment for ADHD highest among children aged 9-12 years, compared with younger or older children (Table) . Rates of medication treatment for ADHD followed the same pattern noted for ADHD diagnosis, such that males of all ages were more likely to have a reported history of ADHD diagnosis and to currently take medication for the disorder (Table) . More males aged 6 years were taking medication for ADHD (4.3%) than females at any age ( Figure 1 ). The highest rates of medication treatment for ADHD by sex and age were reported among males aged 12 years (9.3%) and among females aged 11 years (3.7%). Medication treatment rates were significantly higher among non-Hispanic, primarily Englishspeaking, and insured children. Geographic variability in prevalence of medication treatment ranged from a low of 2.1% in California to a high of 6.5% in Arkansas (Figure 2) . Nationally, 56.3% of children with reported ADHD diagnoses were being treated with medication at the time of the survey. The frequency of medication treatment among males and females with reported ADHD diagnoses was not significantly different (56.8% versus 55.0%, respectively). Rates of medication treatment among those with a reported diagnosis This report is also the first to document national and statespecific prevalence of medication treatment for ADHD using national survey data. Although ADHD is considered a chronic condition, to what extent the "ever" diagnosed rate reflects current levels of clinical symptomatology is unclear. However, because children with ADHD often are not treated with medication, current medication treatment prevalence can serve as a minimum estimate of overall ADHD prevalence.
Several factors affect determination of the most appropriate ADHD therapy for children; however, clinical treatment guidelines exist that recommend efficacious pharmacologic and behavioral interventions (7) (8) . NSCH does not assess use of ADHD treatments other than medication. Thus, the number of children with reported ADHD diagnoses who received other types of treatments is not known. Children in racial/ethnic minority populations and uninsured children were less likely than others to be taking medication for ADHD. Additional research is warranted to investigate differential patterns in diagnosis and treatment of ADHD across demographic and geographic strata.
The findings in this report are subject to at least four limitations. First, because the data are based on parental reports of ADHD diagnosis and medication treatment, the accuracy of these reports are subject to recall bias, telephone survey selection biases, and other types of response errors. Second, the survey sampling design excluded institutionalized persons, who might have higher rates of ADHD and medication treatment. Third, the survey was only administered in English or Spanish and therefore excluded families speaking neither language. Finally, these data do not include undiagnosed ADHD or children without an ADHD diagnosis who are taking medication for similar symptoms.
This analysis was limited to two relevant NSCH questions pertaining to ADHD and cannot fully characterize current ADHD treatment patterns. No known national survey currently assesses ADHD-related impairment or the nature and extent of treatment for ADHD. Such data are necessary to characterize community care and might inform future public health action.
ADHD poses substantial costs both to families and society. The disorder has been associated with strained familial and peer relationships, suboptimal educational achievement, and increased risk for unintentional injuries (1, 7, 8) . Health-care costs associated with ADHD are conservatively estimated at $3.3 billion annually (9) . Moreover, persistent and negative side effects of stimulants have been documented, including sleep disturbances, reduced appetite, and suppressed growth, which might have important health implications for the millions of children who are currently taking medication for ADHD. Continued monitoring and community-based research activities that focus on sociodemographic and geographic variation in ADHD diagnosis and treatment are needed (10).
Children and Teens Told by Doctors That They Were OverweightUnited States, 1999-2002
The percentage of children and teens aged 6-19 years in the United States who are overweight nearly tripled to 16% during 1980-2002 (1). Overweight and obese children and teens are at greater risk for many comorbid conditions, both immediate and long-term (2) . Their risk is approximately 10 times greater than that of normal weight children for hypertension in young adulthood, three to eight times greater for dyslipidemias, and more than twice as great for diabetes mellitus (2) . To determine what percentage of overweight children (or their parents) and teens were ever told their weight status by doctors or other health-care professionals, CDC analyzed data from the 1999-2002 National Health and Nutrition Examination Survey (NHANES). This report summarizes the results of that analysis, which determined that 36.7% of overweight children and teens aged 2-19 years had been told by a doctor or other health-care professional that they were overweight, and teens aged 16-19 years were more likely to be told than parents of children aged 2-11 years. By discussing weight status with overweight patients and their parents, pediatric health-care providers might help these patients implement lifelong improvements in diet and physical activity.
NHANES is an ongoing series of cross-sectional surveys on health and nutrition designed to be nationally representative of the noninstitutionalized, U.S. civilian population by using a complex, multistage probability design.* During 1999-2002, populations of persons aged 12-19 years, non-Hispanic blacks, and Mexican Americans were among those oversampled. The analyses described in this report include data from 1,473 children and teens aged 2-19 years who were determined to be overweight. This sample represented the approximately 10.3% of U.S. children aged 2-5 years and 16.0% of children and teens aged 6-19 years who were overweight. Overweight was defined as having a body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared) >95th percentile on the BMI-for-age, sex-specific 2000 CDC growth charts for the United States. † Parents of overweight children aged 2-11 years were asked, "Has a doctor or health professional ever told you that [child] was overweight?" Parents of those aged 12-15 years were asked, "Has a doctor or health professional ever told [child] that he/ she was overweight?" Teens aged 16-19 years were asked, "Has a doctor or health professional ever told you that you were overweight?" Results were stratified by sex and age and by sex and race/ ethnicity. Pregnant females were excluded from analysis. Weighted prevalence estimates were calculated. A chi-square test for trend was performed to evaluate the effect of age. Individual t-tests were performed to test differences between racial/ethnic populations. The cutoff for statistical significance was p = 0.05. Bonferroni adjustments were used to account for multiple comparisons between racial/ethnic populations.
Among all overweight children and teens aged 2-19 years (or their parents), 36.7% reported having ever been told by a doctor or health-care professional that they were overweight (Table) . A significant increasing trend (p<0.05) by age group was observed in the percentage of the overall sample told that they were overweight (17.4% for ages 2-5 years, 32.6% for ages 6-11 years, 39.6% for ages 12-15 years, and 51.6% for ages 16-19 years). Similar trends by age group were observed among males and females. Among racial/ethnic populations, overweight non-Hispanic black females were significantly more likely to be told that they were overweight than non-Hispanic white females (47.4% versus 31.0%). Among those informed of overweight status, 39% of non-Hispanic black females were severely overweight (BMI >99th percentile for age and sex), compared with 17% of non-Hispanic white females. Editorial Note: Annual well-child visits to health-care professionals should include measurement of BMI to determine weight status, as recommended by the American Academy of Pediatrics (3). Without intervention, many overweight children will grow up to be overweight or obese adults (4, 5) . The following four behavioral strategies are recommended for families with overweight children: controlling the environment, monitoring behavior, setting goals, and rewarding successful changes in behavior (6) . Families with overweight children might be more motivated to make these changes if they are recommended by a doctor or health-care professional.
In a study of adults who had visited their physicians for routine checkups during the preceding 12 months, fewer than half of those classified as obese (i.e., BMI >30 kg/m 2 ) reported being advised by their health-care professionals to lose weight (7) . A study of 473 children in Kentucky determined that overweight condition had been diagnosed in only 29% of 93 overweight children (i.e., BMI >95th percentile); however, that study did not report whether the diagnoses were shared with children and parents (8) .
In the study described in this report, significant differences in being informed of overweight status were observed by age group and race/ethnicity. For example, 51.6% of teens aged 16-19 years were informed of their overweight status, but only 17.4% of parents of children aged 2-5 years were informed, possibly suggesting reluctance by health-care providers to inform parents of the weight status of very young overweight children. In addition, non-Hispanic black females were more likely to be told that they were overweight than were non-Hispanic white females. However, 39% of nonHispanic black females informed of overweight status were severely overweight, compared with 17% of non-Hispanic white females. Health-care providers might have been more likely to discuss weight status with patients who were severely overweight.
The findings in this report are subject to at least three limitations. First, NHANES data are cross-sectional and therefore cannot capture information about duration of overweight in these children and teens; a longer duration of overweight might have made a provider more likely to inform a child or parent of the child's overweight status. Second, teens might have had more visits to a health-care professional than young children and therefore more opportunities to be told of their overweight status; however, multiple logistic regression controlling for number of health-care visits during the preceding year produced similar results. Third, the question regarding being told of overweight status was asked of parents for children and teens ages 2-15 years and of teens themselves for those aged 16-19 years. Overweight teens might answer this question differently than parents of overweight children, resulting in either a lesser or greater difference among age groups in reports of being told of overweight status.
Among overweight children who become obese adults, earlier onset of childhood overweight is associated with higher BMI in adulthood (9) . Previous findings suggest that children begin to respond to environmental cues regarding dietary patterns by age 5 years (10). Thus, early recognition and discussion of overweight status is a necessary first step to developing healthier lifelong behaviors. Addressing overweight among children and teens requires recognition by health-care providers, discussion of potential consequences with families, acknowledgment of those consequences by families of affected children, and a commitment to work together toward attaining a healthier lifestyle (6). Influenza vaccine distribution delays or vaccine supply shortages have occurred in the United States in three of the last five influenza seasons (1,2) . In response, prioritization has been implemented in previous years to ensure that enough vaccine is available for those at the highest risk for complications from influenza (3). The information in this report updates projections of influenza vaccine supply and previous recommendations for priority use of trivalent inactivated influenza vaccine (TIV) during the 2005-06 influenza season (4).
Four manufacturers now expect to provide influenza vaccine to the U.S. population during the 2005-06 influenza season (Table) . Sanofi Pasteur, Inc., projects production of 60 million doses of TIV. Chiron Corporation projects production of 18-26 million doses of TIV. GlaxoSmithKline (GSK), Inc., whose license application was approved by the Food and Drug Administration on August 31, 2005, projects production of 8 million doses of TIV. MedImmune Vaccines, Inc., producer of live attenuated influenza vaccine (LAIV), projects production of approximately 3 million doses. However, because of the uncertainties regarding production of influenza vaccine, the exact number of available doses and timing of vaccine distribution for the 2005-06 influenza season remain unknown.
Given the uncertainties in doses and distribution, CDC recommends that the following priority groups receive TIV until October 24, 2005:
• persons aged >65 years with comorbid conditions • residents of long-term-care facilities • persons aged 2-64 years with comorbid conditions • persons aged >65 years without comorbid conditions • children aged 6-23 months • pregnant women • health-care personnel who provide direct patient care • household contacts and out-of-home caregivers of children aged <6 months These groups correspond to tiers 1A-1C in the table of TIV priority groups that was published previously in the event of vaccination supply disruption (4). Beginning October 24, 2005, all persons will be eligible for vaccination.
The tiered use of prioritization is not recommended for LAIV administration. LAIV may be administered at any time for vaccination of nonpregnant healthy persons aged 5-49 years, including most health-care personnel, other persons in close contact with groups at high risk for influenza-related complications, and others desiring protection against influenza (5). Additional information is available at http:// www.cdc.gov/flu. * Includes children whose parents reported that they had "definite or severe difficulties," based on response to the question, "Overall, do you think that [child] has a difficulty with emotions, concentration, behavior, or being able to get along with others?" † Includes contact or visit with a mental health professional (i.e., psychiatrist, psychologist, clinical social worker, or psychiatric nurse) during the preceding 12 months, visit with a general physician (i.e., a physician in general practice, pediatrics, family medicine, or internal medicine) for an emotional or behavioral difficulty during the preceding 12 months, or receipt of special education services for an emotional or behavioral difficulty. A child might have received more than one type of service.
In 2003, among the 2.7 million U.S. children aged 4-17 years for whom parents reported definite or severe emotional or behavioral difficulties (5% of all children in that age group), nearly two thirds had had contact with a mental health professional or general physician or had used special education services for those difficulties. 20 
